Applications of machine learning in drug discovery and development
暂无分享,去创建一个
Parantu K. Shah | I. Dunham | A. Madabhushi | Shanrong Zhao | J. Vamathevan | M. Spitzer | P. Shah | Paul Czodrowski | George Lee | Dominic Clark | Edgardo Ferran | Bin Li | P. Czodrowski
[1] A. Butte,et al. A call for deep-learning healthcare , 2019, Nature Medicine.
[2] J. Dean,et al. A guide to deep learning in healthcare , 2019, Nature Medicine.
[3] Volkan Atalay,et al. Recent applications of deep learning and machine intelligence on in silico drug discovery: methods, tools and databases , 2018, Briefings Bioinform..
[4] Chi Heem Wong,et al. Estimation of clinical trial success rates and related parameters , 2018, Biostatistics.
[5] Olexandr Isayev,et al. Transforming Computational Drug Discovery with Machine Learning and AI. , 2018, ACS medicinal chemistry letters.
[6] Jin Gu,et al. VASC: Dimension Reduction and Visualization of Single-cell RNA-seq Data by Deep Variational Autoencoder , 2018, Genom. Proteom. Bioinform..
[7] Geoffrey E. Hinton. Deep Learning-A Technology With the Potential to Transform Health Care. , 2018, JAMA.
[8] N. Razavian,et al. Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning , 2018, Nature Medicine.
[9] A. Madabhushi,et al. Spatial Architecture and Arrangement of Tumor-Infiltrating Lymphocytes for Predicting Likelihood of Recurrence in Early-Stage Non–Small Cell Lung Cancer , 2018, Clinical Cancer Research.
[10] Mary E. Haas,et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations , 2018, Nature Genetics.
[11] R. Morita,et al. Multi-omics monitoring of drug response in rheumatoid arthritis in pursuit of molecular remission , 2018, Nature Communications.
[12] A. Zhavoronkov,et al. Machine Learning on Human Muscle Transcriptomic Data for Biomarker Discovery and Tissue-Specific Drug Target Identification , 2018, Front. Genet..
[13] A. Madabhushi,et al. Nuclear shape and orientation features from H&E images predict survival in early-stage estrogen receptor-positive breast cancers , 2018, Laboratory Investigation.
[14] Mary E. Haas,et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations , 2018, Nature Genetics.
[15] Hugo Ceulemans,et al. Large-scale comparison of machine learning methods for drug target prediction on ChEMBL† †Electronic supplementary information (ESI) available: Overview, Data Collection and Clustering, Methods, Results, Appendix. See DOI: 10.1039/c8sc00148k , 2018, Chemical science.
[16] Virginia B. Kraus,et al. Biomarkers as drug development tools: discovery, validation, qualification and use , 2018, Nature Reviews Rheumatology.
[17] Thomas Blaschke,et al. The rise of deep learning in drug discovery. , 2018, Drug discovery today.
[18] Colin C. Pritchard,et al. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease , 2018, Journal of Immunotherapy for Cancer.
[19] Michael Peyton,et al. Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer , 2018, Cell.
[20] Yongfeng Huang,et al. Clinical Assistant Diagnosis for Electronic Medical Record Based on Convolutional Neural Network , 2018, Scientific Reports.
[21] Rajarsi R. Gupta,et al. Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. , 2018, Cell reports.
[22] Andrew Janowczyk,et al. A deep-learning classifier identifies patients with clinical heart failure using whole-slide images of H&E tissue , 2018, PloS one.
[23] Mike Preuss,et al. Planning chemical syntheses with deep neural networks and symbolic AI , 2017, Nature.
[24] Sepp Hochreiter,et al. Fréchet ChemNet Distance: A Metric for Generative Models for Molecules in Drug Discovery , 2018, J. Chem. Inf. Model..
[25] Seth A Ament,et al. Transcriptional regulatory networks underlying gene expression changes in Huntington's disease , 2018, Molecular systems biology.
[26] Dmitrii Bychkov,et al. Deep learning based tissue analysis predicts outcome in colorectal cancer , 2018, Scientific Reports.
[27] M. Hutson. Artificial intelligence faces reproducibility crisis. , 2018, Science.
[28] Amir Barati Farimani,et al. Binding Pathway of Opiates to μ-Opioid Receptors Revealed by Machine Learning , 2018, 1804.08206.
[29] Harry Hemingway,et al. Machine learning models in electronic health records can outperform conventional survival models for predicting patient mortality in coronary artery disease , 2018, bioRxiv.
[30] David J. Nicholls,et al. Impact of a five-dimensional framework on R&D productivity at AstraZeneca , 2018, Nature Reviews Drug Discovery.
[31] Thomas George Olsen,et al. Diagnostic Performance of Deep Learning Algorithms Applied to Three Common Diagnoses in Dermatopathology , 2018, Journal of pathology informatics.
[32] Bo Zhu,et al. MR fingerprinting Deep RecOnstruction NEtwork (DRONE) , 2017, Magnetic resonance in medicine.
[33] Joseph Gomes,et al. MoleculeNet: a benchmark for molecular machine learning† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c7sc02664a , 2017, Chemical science.
[34] Pankaj Agarwal,et al. Systematic interrogation of diverse Omic data reveals interpretable, robust, and generalizable transcriptomic features of clinically successful therapeutic targets , 2017, bioRxiv.
[35] Russ P Carstens,et al. ESRP1 Mutations Cause Hearing Loss due to Defects in Alternative Splicing that Disrupt Cochlear Development. , 2017, Developmental cell.
[36] Olaf Hellwich,et al. Deep convolutional neural networks for automatic classification of gastric carcinoma using whole slide images in digital histopathology , 2017, Comput. Medical Imaging Graph..
[37] John F. McDonald,et al. Open source machine-learning algorithms for the prediction of optimal cancer drug therapies , 2017, PloS one.
[38] Ziv Bar-Joseph,et al. Dhaka: Variational Autoencoder for Unmasking Tumor Heterogeneity from Single Cell Genomic Data , 2017, bioRxiv.
[39] Taner Z. Sen,et al. The art of curation at a biological database: Principles and application , 2017 .
[40] A. Condon,et al. Interpretable dimensionality reduction of single cell transcriptome data with deep generative models , 2017, bioRxiv.
[41] P. Sanseau,et al. In silico prediction of novel therapeutic targets using gene–disease association data , 2017, Journal of Translational Medicine.
[42] Casey S. Greene,et al. Extracting a Biologically Relevant Latent Space from Cancer Transcriptomes with Variational Autoencoders , 2017, bioRxiv.
[43] Sergey Nikolenko,et al. druGAN: An Advanced Generative Adversarial Autoencoder Model for de Novo Generation of New Molecules with Desired Molecular Properties in Silico. , 2017, Molecular pharmaceutics.
[44] A. Madabhushi,et al. An oral cavity squamous cell carcinoma quantitative histomorphometric-based image classifier of nuclear morphology can risk stratify patients for disease-specific survival , 2017, Modern Pathology.
[45] Andreas Verras,et al. Is Multitask Deep Learning Practical for Pharma? , 2017, J. Chem. Inf. Model..
[46] George Papadatos,et al. Beyond the hype: deep neural networks outperform established methods using a ChEMBL bioactivity benchmark set , 2017, bioRxiv.
[47] Phillip G. Montgomery,et al. Defining a Cancer Dependency Map , 2017, Cell.
[48] P. Sanseau,et al. In silico prediction of novel therapeutic targets using gene–disease association data , 2017, Journal of Translational Medicine.
[49] Haiying Xu,et al. Abstract 662: The differential association of PD-1, PD-L1, and CD8+ cells with response to pembrolizumab and presence of Merkel cell polyomavirus (MCPyV) in patients with Merkel cell carcinoma (MCC) , 2017 .
[50] Xian Zhang,et al. A multi‐scale convolutional neural network for phenotyping high‐content cellular images , 2017, Bioinform..
[51] Andrew Janowczyk,et al. A deep learning based strategy for identifying and associating mitotic activity with gene expression derived risk categories in estrogen receptor positive breast cancers , 2017, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[52] Andrew H. Beck,et al. Morphoproteomic Characterization of Lung Squamous Cell Carcinoma Fragmentation, a Histological Marker of Increased Tumor Invasiveness. , 2017, Cancer research.
[53] D. Mohr,et al. Personal Sensing: Understanding Mental Health Using Ubiquitous Sensors and Machine Learning. , 2017, Annual review of clinical psychology.
[54] Ranadip Pal,et al. IntegratedMRF: random forest‐based framework for integrating prediction from different data types , 2017, Bioinform..
[55] Qi Wang,et al. A novel framework for the identification of drug target proteins: Combining stacked auto-encoders with a biased support vector machine , 2017, PloS one.
[56] Barend Mons,et al. Bridging the translational innovation gap through good biomarker practice , 2017, Nature Reviews Drug Discovery.
[57] Thomas Blaschke,et al. Molecular de-novo design through deep reinforcement learning , 2017, Journal of Cheminformatics.
[58] Anant Madabhushi,et al. Accurate and reproducible invasive breast cancer detection in whole-slide images: A Deep Learning approach for quantifying tumor extent , 2017, Scientific Reports.
[59] R. Dobson,et al. Characterisation of mental health conditions in social media using Informed Deep Learning , 2017, Scientific Reports.
[60] Wei Q. Deng,et al. A machine-learning heuristic to improve gene score prediction of polygenic traits , 2017, Scientific Reports.
[61] Jun S. Song,et al. Maximum entropy methods for extracting the learned features of deep neural networks , 2017, bioRxiv.
[62] Feng Lin,et al. Low-Dose CT With a Residual Encoder-Decoder Convolutional Neural Network , 2017, IEEE Transactions on Medical Imaging.
[63] Yoseph Barash,et al. Integrative deep models for alternative splicing , 2017, bioRxiv.
[64] Hyunju Lee,et al. An analysis of disease-gene relationship from Medline abstracts by DigSee , 2017, Scientific Reports.
[65] Saeed Hassanpour,et al. Deep Learning for Classification of Colorectal Polyps on Whole-slide Images , 2017, Journal of pathology informatics.
[66] Gautier Koscielny,et al. Open Targets: a platform for therapeutic target identification and validation , 2016, Nucleic Acids Res..
[67] George Papadatos,et al. The ChEMBL database in 2017 , 2016, Nucleic Acids Res..
[68] George Lee,et al. Nuclear Shape and Architecture in Benign Fields Predict Biochemical Recurrence in Prostate Cancer Patients Following Radical Prostatectomy: Preliminary Findings. , 2016, European urology focus.
[69] Bo Wang,et al. Visualization and analysis of single-cell RNA-seq data by kernel-based similarity learning , 2016, Nature Methods.
[70] Mannudeep K. Kalra,et al. Low-Dose CT with a Residual Encoder-Decoder Convolutional Neural Network (RED-CNN) , 2017, ArXiv.
[71] Yasen Jiao,et al. Performance measures in evaluating machine learning based bioinformatics predictors for classifications , 2016, Quantitative Biology.
[72] Pankaj Agarwal,et al. Systematic Analysis of Drug Targets Confirms Expression in Disease-Relevant Tissues , 2016, Scientific Reports.
[73] Stefan Kramer,et al. Filtered circular fingerprints improve either prediction or runtime performance while retaining interpretability , 2016, Journal of Cheminformatics.
[74] L. Pusztai,et al. Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer , 2016, Breast Cancer Research.
[75] Emanuel J. V. Gonçalves,et al. A Landscape of Pharmacogenomic Interactions in Cancer , 2016, Cell.
[76] O. Stegle,et al. Deep learning for computational biology , 2016, Molecular systems biology.
[77] Andrew Janowczyk,et al. Automated Tubule Nuclei Quantification and Correlation with Oncotype DX risk categories in ER+ Breast Cancer Whole Slide Images , 2016, Scientific Reports.
[78] Juan González-Vallinas,et al. A new view of transcriptome complexity and regulation through the lens of local splicing variations , 2016, eLife.
[79] C. Greene,et al. ADAGE-Based Integration of Publicly Available Pseudomonas aeruginosa Gene Expression Data with Denoising Autoencoders Illuminates Microbe-Host Interactions , 2016, mSystems.
[80] Andrew Janowczyk,et al. Deep learning for digital pathology image analysis: A comprehensive tutorial with selected use cases , 2016, Journal of pathology informatics.
[81] N. Linder,et al. Antibody-supervised deep learning for quantification of tumor-infiltrating immune cells in hematoxylin and eosin stained breast cancer samples , 2016, Journal of pathology informatics.
[82] Samuel Kaski,et al. Sparse group factor analysis for biclustering of multiple data sources , 2015, Bioinform..
[83] Ney Lemke,et al. Prediction of Druggable Proteins Using Machine Learning and Systems Biology: A Mini-Review , 2015, Front. Physiol..
[84] David Allman,et al. Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. , 2015, Cancer discovery.
[85] E. Pierson,et al. ZIFA: Dimensionality reduction for zero-inflated single-cell gene expression analysis , 2015, Genome Biology.
[86] Mulin Jun Li,et al. Nature Genetics Advance Online Publication a N a Ly S I S the Support of Human Genetic Evidence for Approved Drug Indications , 2022 .
[87] Yuri Nikolsky,et al. Development of a Drug-Response Modeling Framework to Identify Cell Line Derived Translational Biomarkers That Can Predict Treatment Outcome to Erlotinib or Sorafenib , 2015, PloS one.
[88] Geoffrey E. Hinton,et al. Deep Learning , 2015, Nature.
[89] Sepp Hochreiter,et al. Toxicity Prediction using Deep Learning , 2015, ArXiv.
[90] Robert P. Sheridan,et al. Deep Neural Nets as a Method for Quantitative Structure-Activity Relationships , 2015, J. Chem. Inf. Model..
[91] Vijay S. Pande,et al. Massively Multitask Networks for Drug Discovery , 2015, ArXiv.
[92] HA Hejase,et al. Improving Drug Sensitivity Prediction Using Different Types of Data , 2015, CPT: pharmacometrics & systems pharmacology.
[93] B. Frey,et al. The human splicing code reveals new insights into the genetic determinants of disease , 2015, Science.
[94] Nci Dream Community. A community effort to assess and improve drug sensitivity prediction algorithms , 2014 .
[95] Philip M. Kim,et al. A systematic approach to identify novel cancer drug targets using machine learning, inhibitor design and high-throughput screening , 2014, Genome Medicine.
[96] Núria Queralt-Rosinach,et al. Extraction of relations between genes and diseases from text and large-scale data analysis: implications for translational research , 2014, BMC Bioinformatics.
[97] Paul Czodrowski,et al. Count on kappa , 2014, Journal of Computer-Aided Molecular Design.
[98] Yuan Wang,et al. Using Information from Historical High-Throughput Screens to Predict Active Compounds , 2014, J. Chem. Inf. Model..
[99] Brendan J. Frey,et al. Deep learning of the tissue-regulated splicing code , 2014, Bioinform..
[100] Nitish Srivastava,et al. Dropout: a simple way to prevent neural networks from overfitting , 2014, J. Mach. Learn. Res..
[101] Maqc Consortium. The MicroArray Quality Control ( MAQC )-II study of common practices for the development and validation of microarray-based predictive models , 2012 .
[102] Andrew H. Beck,et al. Systematic Analysis of Breast Cancer Morphology Uncovers Stromal Features Associated with Survival , 2011, Science Translational Medicine.
[103] Edward S. Kim,et al. The BATTLE trial: personalizing therapy for lung cancer. , 2011, Cancer discovery.
[104] P.A.C.R. Costa,et al. A machine learning approach for genome-wide prediction of morbid and druggable human genes based on systems-level data , 2010, BMC Genomics.
[105] Kevin C. Dorff,et al. The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models , 2010, Nature Biotechnology.
[106] S. Koscielny. Why Most Gene Expression Signatures of Tumors Have Not Been Useful in the Clinic , 2010, Science Translational Medicine.
[107] Andrew J. Doig,et al. Properties and identification of human protein drug targets , 2009, Bioinform..
[108] Laurence Lodé,et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[109] John D. Shaughnessy,et al. High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone. , 2008, Blood.
[110] Luhua Lai,et al. Prediction of potential drug targets based on simple sequence properties , 2007, BMC Bioinformatics.
[111] Michael J. Keiser,et al. Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.
[112] Anthony Boral,et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. , 2006, Blood.
[113] Yongsheng Huang,et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. , 2006, Blood.
[114] John Crowley,et al. The molecular classification of multiple myeloma. , 2006, Blood.
[115] Geoffrey E. Hinton,et al. Reducing the Dimensionality of Data with Neural Networks , 2006, Science.
[116] B. Honig,et al. On the nature of cavities on protein surfaces: Application to the identification of drug‐binding sites , 2006, Proteins.
[117] R W Veltri,et al. Quantitative nuclear grade (QNG): A new image analysis‐based biomarker of clinically relevant nuclear structure alterations , 2000, Journal of cellular biochemistry. Supplement.